Stockholm 17:30
0,00% Idag
-0,23% Sedan årsskifte
-0,01% OMXSPI

2018-12-17 08:35:00

CombiGene approved for listing on Nasdaq First North Stockholm and first day of trading is Wednesday 19 December 2018

Nasdaq Stockholm AB has decided that the shares and subscription warrants (TO2) of CombiGene AB (publ) will be traded on Nasdaq First North Stockholm. The first day of trading is December 19, 2018.

The shares and the subscription rights will be traded with unchanged ticker (COMBI) and ISIN-Code (SE0006504593) for the share and (COMBI TO 2) and ISIN-code (SE0011616408) for the subscription rights.

No offer or issuing of new shares will be made in connection with the change from Spotlight Stock Market to Nasdaq First North Stockholm and the Company's shareholders doesn't need to take any actions in connection with the change.

"The change to Nasdaq First North will increase the awareness of CombiGene and attract a larger group of investors and accordingly it will give the company better access to both Swedish and International capital" says Jan Nilsson CEO of CombiGene"

The Company has also produced a company description, which is available on the Company's website,

FNCA Sweden AB has been engaged as Certified Adviser for CombiGene AB on Nasdaq First North Stockholm

CombiGene AB (publ)

Jan Nilsson, VD
Tel: +46 (0)704 66 31 63

About CombiGene AB

CombiGene's business concept is to develop effective gene therapies for treatment of difficult-to-treat diseases for which adequate treatment methods are currently lacking. The company intends to take its candidate drugs through the phases of preclinical development and initial clinical studies under its own management, and subsequently continue development and commercialization in collaboration with other partners. Founded on the basis of scientific discoveries made at Lund University and the University of Copenhagen, CombiGene has offices at Medicon Village in Lund, Sweden. The company is public and listed on the Swedish marketplace Spotlight.

Attached html: HTML
Attached pdf: PDF